A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
A Phase 1, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: SCG Cell Therapy
- Phone Number: 021-50339500
- Email: clinicaltrials@scgcell.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100020
- Recruiting
- Beijing
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Guangzhou
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Zhengzhou
-
-
Jilin
-
Chang chun, Jilin, China, 130000
- Recruiting
- Changchun
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Recruiting
- Shenyang
-
-
Shandong
-
Ji'nan, Shandong, China, 250000
- Recruiting
- Ji'nan
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Shanghai
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)
- Subjects with HCC who have received standard systemic therapies
- HLA-A *02
- BCLC stage B or C
- Child-pugh score ≤ 7 ol
- Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be ≤ 1 × 1000 IU/ml
- Have at least one measurable leasion at baseline as per mRECIST and iRECIST
- Life expectancy of 3 months or greater
- The organ function is in good condition.
Exclusion Criteria:
- Subjects with history of another primary cancer within 5 years
- Central nervous system metastasis and clinically significant central nervous system disease
- Previous or current coexistence of hepatic encephalopathy
- Currently present with symptomatic third space fluid accumulation
- Hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment)
- Known history of neurological or mental disorder, including epilepsy or dementia
- Suffering from active autoimmune diseases, or other significant ongoing immune rejection based on pathology and clinical diagnosis
- Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy
- Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgM antibody; or there is current evidence indicating the presence of HEV infection
- Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)
- Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SCG101
|
Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of dose-limiting toxicity (DLT) and adverse events (AEs), including serious AEs (SAEs), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).
Time Frame: Start of SCG101 infusion until disease progression or 12 months post infusion
|
Based on incidence of adverse events (AE) using NCI-CTCAE v5.0 and ASTCT criteria
|
Start of SCG101 infusion until disease progression or 12 months post infusion
|
|
The preliminary clinical efficacy of SCG101, including objective response rate (ORR), disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS).
Time Frame: Start of SCG101 infusion until disease progression or 12 months post infusion
|
Per mRECIST and iRECIST
|
Start of SCG101 infusion until disease progression or 12 months post infusion
|
|
Change in pharmacodynamics markers (PD) before and after SCG101 infusion
Time Frame: Start of SCG101 infusion until disease progression, an average of 24 months
|
Based on changes in serum liver function markers, including HBsAg, ALT, AST, and AFP
|
Start of SCG101 infusion until disease progression, an average of 24 months
|
|
Persistences of viral vector copy number (VCN) after SCG101 infusion
Time Frame: Start of SCG101 infusion until disease progression, an average of 24 months
|
Start of SCG101 infusion until disease progression, an average of 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Liver Neoplasms
- Enterovirus Infections
- Picornaviridae Infections
- Carcinoma
- Hepatitis B
- Hepatitis
- Carcinoma, Hepatocellular
- Hepatitis A
Other Study ID Numbers
Other Study ID Numbers
- SCG-101-CR-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.